1. A NEW BCL‐2 INHIBITOR (S55746/BCL201) AS MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY NON‐HODGKIN LYMPHOMA: PRELIMINARY RESULTS OF THE FIRST‐IN‐HUMAN STUDY. (June 2017) Authors: Le Gouill, S.; Wermke, M.; Morschhauser, F.; Lim, S.T.; Salles, G.; Kloos, I.; de Burgat, V.; Becquart, M.; Paux, G.; Kraus‐Berthier, L.; Pennaforte, S.; Stilgenbauer, S.; Walewski, J.; Ribrag, V. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 47 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. AN IMPROVED BENEFIT‐RISK PROFILE OF DUVELISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA WHO RECEIVED 2 OR MORE PRIOR THERAPIES. (12th June 2019) Authors: Flinn, I.W.; Davids, M.S.; Hillmen, P.; Montillo, M.; Delgado, J.; Kuss, B.J.; Tam, C.S.; Jäger, U.; Ghia, P.; Stilgenbauer, S.; Lustgarten, S.; Weaver, D.T.; Youssoufian, H.; Cymbalista, F. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 213 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. AUTOLOGOUS STEM CELL TRANSPLANTATION IN FIRST REMISSION SIGNIFICANTLY PROLONGS PROGRESSION‐FREE AND OVERALL SURVIVAL IN MANTLE CELL LYMPHOMA. (12th June 2019) Authors: Zoellner, A.; Unterhalt, M.; Stilgenbauer, S.; Hübel, K.; Thieblemont, C.; Metzner, B.; Kluin‐Nelemans, H.; Hiddemann, W.; Dreyling, M.; Hoster, E. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 43 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. BENDAMUSTINE (B), FOLLOWED BY OBINUTUZUMAB (G) AND VENETOCLAX (A) IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): CLL2‐BAG TRIAL OF THE GERMAN CLL STUDY GROUP (GCLLSG). (June 2017) Authors: Cramer, P.; von Tresckow, J.; Bahlo, J.; Robrecht, S.; Al‐Sawaf, O.; Langerbeins, P.; Engelke, A.; Fink, A.M.; Fischer, K.; Seiler, T.; von Weikersthal, L.Fischer; Hebart, H.; Kreuzer, K.A.; Ritgen, M.; Kneba, M.; Wendtner, C.M.; Stilgenbauer, S.; Eichhorst, B.; Hallek, M. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 25 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. CHARACTERISTICS, TREATMENT, AND OUTCOMES OF ≥ 80 YEAR OLD PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) ENROLLED TO PROSPECTIVE TRIALS OF THE GERMAN CLL STUDY GROUP. (June 2017) Authors: Al‐Sawaf, O.; Bahlo, J.; Fischer, K.; Herling, C.; Bergmann, M.; Fink, A.M.; von Tresckow, J.; Langerbeins, P.; Cramer, P.; Stilgenbauer, S.; Wendtner, C.M.; Eichhorst, B.; Hallek, M.; Goede, V. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 99 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. EFFECT OF DOSE MODIFICATIONS ON RESPONSE TO DUVELISIB IN PATIENTS WITH RELAPSED/REFRACTORY CLL/SLL IN THE DUO TRIAL. (12th June 2019) Authors: Ghia, P.; Flinn, I.W.; Lamanna, N.; Montillo, M.; Illés, Á.; Etienne, G.; Delgado, J.; Kuss, B.J.; Tam, C.S.; Offner, F.; Bosch, F.; Davids, M.S.; Jäger, U.; Cymbalista, F.; Weaver, D.T.; Lustgarten, S.; Youssoufian, H.; Stilgenbauer, S. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 214 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. FIXED‐DURATION VENETOCLAX PLUS OBINUTUZUMAB IMPROVES PFS AND MINIMAL RESIDUAL DISEASE NEGATIVITY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL AND COMORBIDITIES. (12th June 2019) Authors: Fischer, K.; Porro Lurà, M.; Al‐Sawaf, O.; Bahlo, J.; Fink, A.; Tandon, M.; Dixon, M.; Robrecht, S.; Warburton, S.; Humphrey, K.; Samoylova, O.; Liberati, A.M.; Pinilla‐Ibarz, J.; Opat, S.; Sivcheva, L.; Le Dû, K.; Fogliatto, L.M.; Utoft Niemann, C.; Weinkove, R.; Robinson, S. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 82 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. GENETIC MARKERS AND OUTCOME IN THE CLL14 TRIAL OF THE GCLLSG COMPARING FRONT LINE OBINUTUZUMAB PLUS CHLORABMUCIL OR VENETOCLAX IN PATIENTS WITH COMORBIDITY Best abstract submitted by a young investigator / travel grant recipient. (12th June 2019) Authors: Tausch, E.; Bahlo, J.; Robrecht, S.; Schneider, C.; Bloehdorn, J.; Schrell, S.; Galler, C.; Al‐Sawaf, O.; Fink, A.; Eichhorst, B.; Kreuzer, K.; Tandon, M.; Humphrey, K.; Jiang, Y.; Schary, W.; Porro Lurà, M.; Döhner, H.; Fischer, K.; Hallek, M.; Stilgenbauer, S. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 84 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. HIGH EFFICACY OF VENETOCLAX PLUS OBINUTUZUMAB IN PATIENTS WITH COMPLEX KARYOTYPE (CKT) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A PROSPECTIVE ANALYSIS FROM THE CLL14 TRIAL. (12th June 2019) Authors: Al‐Sawaf, O.; Lilienweiss, E.; Bahlo, J.; Robrecht, S.; Fink, A.; Patz, M.; Tandon, M.; Humphrey, K.; Jiang, Y.; Schary, W.; Porro Lurà, M.; Ritgen, M.; Tausch, E.; Stilgenbauer, S.; Eichhorst, B.; Fischer, K.; Hallek, M.; Kreuzer, K. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 104 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT‐NAÏVE EARLY STAGE CLL: PRIMARY ENDPOINT RESULTS OF THE PHASE 3 DOUBLE‐BLIND RANDOMIZED CLL12 TRIAL. (12th June 2019) Authors: Langerbeins, P.; Bahlo, J.; Rhein, C.; Gerwin, H.; Cramer, P.; Fürstenau, M.; Al‐Sawaf, O.; von Tresckow, J.; Fink, A.M.; Kreuzer, K.; Vehling‐Kaiser, U.; Tausch, E.; Müller, L.; Eckart, M.; Schlag, R.; Freier, W.; Gaska, T.; Balser, C.; Reiser, M.; Stauch, M. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 38 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗